Argenx SE

Argenx combines the diversity of the llama immune system with antibody engineering advancing a clinical pipeline to treat patients with cancer and severe autoimmune diseases. Argenx’s platforms allow the company to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect.

Foresite Capital first invested in Argenx during their US initial public offering in the spring of 2017. Argenx has made considerable progress in the past 2 years, with the advancement of several drug candidates into clinical development in both autoimmune and oncology indications. Additionally, the company has brought in extensive non-dilutive financing and recently signed a business development deal with AbbVie for a $40M upfront payment (with $625M in potential milestones) for a pre-clinical drug candidate. Argenx has expedited development on a novel drug candidate, Argx-113, which has the potential to treat certain autoimmune diseases. We believe this technology could be highly disruptive and displace the standard of care (plasma exchange and IV-Ig) for a variety of conditions involving pathogenic autoimmune antibodies.